Moderate Pain - Pipeline Review, H1 2015

Moderate Pain - Pipeline Review, H1 2015

Moderate Pain - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Moderate Pain - Pipeline Review, H1 2015’, provides an overview of the Moderate Pain’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Moderate Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Moderate Pain and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Moderate Pain
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Moderate Pain and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Moderate Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Moderate Pain pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Moderate Pain
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Moderate Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Introduction 7
Global Markets Direct Report Coverage 7
Moderate Pain Overview 8
Therapeutics Development 9
Pipeline Products for Moderate Pain - Overview 9
Pipeline Products for Moderate Pain - Comparative Analysis 10
Moderate Pain - Therapeutics under Development by Companies 11
Moderate Pain - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Moderate Pain - Products under Development by Companies 16
Moderate Pain - Companies Involved in Therapeutics Development 18
A. Menarini Industrie Farmaceutiche Riunite Srl 18
Acura Pharmaceuticals, Inc. 19
Egalet Corporation 20
KemPharm, Inc. 21
Laboratorios Del Dr. Esteve S.A. 22
Lumosa Therapeutics Co., Ltd. 23
Nektar Therapeutics 24
Pain Therapeutics, Inc. 25
Pfizer Inc. 26
Relmada Therapeutics, Inc. 27
Trevena, Inc. 28
Moderate Pain - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Combination Products 30
Assessment by Target 31
Assessment by Mechanism of Action 33
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 38
(acetaminophen + oxycodone hydrochloride) IR - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
(benzhydrocodone hydrochloride + acetaminophen) - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
(celecoxib + tramadol hydrochloride) - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
(dexketoprofen trometamol + tramadol hydrochloride) - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
(oxycodone hydrochloride + naltrexone) ER - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
buprenorphine hydrochloride ER - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Egalet-003 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
ELS-130 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
hydromorphone hydrochloride IR - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
levorphanol tartrate ER - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
LT-1001 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
methadone IR - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
morphine sulfate ER - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
morphine sulfate IR - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
NKTR-181 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
NKTR-194 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
oxycodone hydrochloride ER - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
oxycodone hydrochloride ER - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
oxymorphone hydrochloride - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
PTI-202 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
PTI-721 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
tramadol hydrochloride IR - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
TRV-734 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Moderate Pain - Recent Pipeline Updates 65
Moderate Pain - Dormant Projects 74
Moderate Pain - Discontinued Products 75
Moderate Pain - Product Development Milestones 76
Featured News & Press Releases 76
Mar 04, 2014: KemPharm Expands Global Intellectual Property Estate for KP201 76
Feb 20, 2014: Egalet Receives Fast Track Designation for Egalet-001 76
Feb 20, 2014: Egalet Receives Fast Track Designation for Egalet-002 for Moderate to Severe Pain 76
Appendix 78
Methodology 78
Coverage 78
Secondary Research 78
Primary Research 78
Expert Panel Validation 78
Contact Us 78
Disclaimer 79

List of Tables

Number of Products under Development for Moderate Pain, H1 2015 9
Number of Products under Development for Moderate Pain - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 12
Comparative Analysis by Late Stage Development, H1 2015 13
Comparative Analysis by Clinical Stage Development, H1 2015 14
Comparative Analysis by Early Stage Development, H1 2015 15
Products under Development by Companies, H1 2015 16
Products under Development by Companies, H1 2015 (Contd..1) 17
Moderate Pain - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2015 18
Moderate Pain - Pipeline by Acura Pharmaceuticals, Inc., H1 2015 19
Moderate Pain - Pipeline by Egalet Corporation, H1 2015 20
Moderate Pain - Pipeline by KemPharm, Inc., H1 2015 21
Moderate Pain - Pipeline by Laboratorios Del Dr. Esteve S.A., H1 2015 22
Moderate Pain - Pipeline by Lumosa Therapeutics Co., Ltd., H1 2015 23
Moderate Pain - Pipeline by Nektar Therapeutics, H1 2015 24
Moderate Pain - Pipeline by Pain Therapeutics, Inc., H1 2015 25
Moderate Pain - Pipeline by Pfizer Inc., H1 2015 26
Moderate Pain - Pipeline by Relmada Therapeutics, Inc., H1 2015 27
Moderate Pain - Pipeline by Trevena, Inc., H1 2015 28
Assessment by Monotherapy Products, H1 2015 29
Assessment by Combination Products, H1 2015 30
Number of Products by Stage and Target, H1 2015 32
Number of Products by Stage and Mechanism of Action, H1 2015 34
Number of Products by Stage and Route of Administration, H1 2015 36
Number of Products by Stage and Molecule Type, H1 2015 37
Moderate Pain Therapeutics - Recent Pipeline Updates, H1 2015 65
Moderate Pain - Dormant Projects, H1 2015 74
Moderate Pain - Discontinued Products, H1 2015 75

List of Figures

Number of Products under Development for Moderate Pain, H1 2015 9
Number of Products under Development for Moderate Pain - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 11
Comparative Analysis by Late Stage Development, H1 2015 13
Comparative Analysis by Clinical Stage Development, H1 2015 14
Assessment by Monotherapy Products, H1 2015 29
Assessment by Combination Products, H1 2015 30
Number of Products by Top 10 Targets, H1 2015 31
Number of Products by Stage and Top 10 Targets, H1 2015 31
Number of Products by Top 10 Mechanism of Actions, H1 2015 33
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 33
Number of Products by Top 10 Routes of Administration, H1 2015 35
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 35
Number of Products by Stage and Top 10 Molecule Types, H1 2015 37
Loading...

We are very sorry, but an error occurred.
Please contact support@reportbuyer.com if the problem remains.